|
|
 |
|
Viewing report
|
|
|
|
Stakeholder Insight: Prostate Cancer - Hormone-Refractory Patients Still Waiting For Treatment Breakthroughs
Datamonitor, Dec 2007, Pages: 249
Introduction
As a result of market dominance by agents such as leuprolide, and AstraZeneca’s Zoladex (goserelin) and Casodex (bicalutamide), there is little space in the antihormonal therapies market for new competition unless significant clinical superiority or a unique selling point is demonstrated. While Taxotere-based chemotherapy is the established first-line standard for hormone-refractory prostate cancer, many patients are still precluded from treatment due to toxicity concerns. This, coupled with a lack of second-line standard therapy, indicates a major gap in the market that could be potentially lucrative for drug developers. Enthusiasm has been shown by key opinion leaders regarding certain late-phase pipeline products, however, during the time of writing, publication of negative clinical trial data has meant a dampening of this optimism. It will therefore be some time before the high unmet needs in the hormone-refractory prostate cancer market are satisfied.
Scope
Identify key factors that influence prescribing patterns for systemic therapy of prostate cancer Examine the significant unmet needs in the prostate cancer market and identify opportunities for new product development Enhance commercial positioning by increasing understanding of current dynamics within the prostate cancer market
Highlights
Reasons to Purchase
Customers who bought this item also bought
Prostate Cancer Therapeutics - Global Strategic Business Report
Strategic Perspectives: Prostate Cancer - Issues in Second-line, Brachytherapy and Hormone-Refractory Prostate Cancer Treatments
Treatment Algorithms 2001: Prostate Cancer
Stakeholder Insight: Prostate Cancer Treatment in the USA
Prostate Cancer - A Therapeutic & Competitive Insight
Prostate Cancer Insight - Profiting From Changing Treatment Patterns
Cancer Drug Discoveries: What the Future Holds: Prostate Cancer Chapter
Stakeholder Insight: Prostate Cancer Treatment and Commercial Issues
Stakeholder Insight: Metastatic And Hormone Refractory Prostate cancer
Prostate Cancer - A Prostrate Market Waiting For Innovations
Stakeholder Insight: Local and Locally Advanced Prostate Cancer
Disease and Therapy Review: Prostate Cancer
|
|
|
|
